[HTML][HTML] Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis
H Bachelez, SE Choon, S Marrakchi… - … England Journal of …, 2019 - Mass Medical Soc
New England Journal of Medicine, 2019•Mass Medical Soc
Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis |
NEJM Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube
LinkedIn Prepare to become a physician, build your knowledge, lead a health care organization,
and advance your career with NEJM Group information and services. NEJM Evidence NEW!
A digital journal for innovative original research and fresh, bold ideas in clinical trial design
and clinical decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth …
NEJM Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube
LinkedIn Prepare to become a physician, build your knowledge, lead a health care organization,
and advance your career with NEJM Group information and services. NEJM Evidence NEW!
A digital journal for innovative original research and fresh, bold ideas in clinical trial design
and clinical decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth …
Interleukin-36 Blockade in Pustular Psoriasis
Seven patients with pustular psoriasis, three with mutations in IL36RN, were treated with a monoclonal antibody against interleukin-36 receptor and had amelioration of their skin disease.
The New England Journal Of Medicine